Derenofylline (SLV 320) is a potent, selective and orally active adenosine A1 receptor antagonist, with Ki values of 1 nM, 200 nM and 398 nM for human A1, A3 and A2A receptors respectively. Derenofylline suppresses cardiac fibrosis and attenuates albuminuria without affecting blood pressure in rats[1].
Derenofylline (SLV 320) is a potent, selective, and orally active adenosine A1 receptor antagonist, with Ki values of 1 nM, 200 nM, and 398 nM for human A1, A3, and A2A receptors, respectively. Derenofylline mitigates cardiac fibrosis and reduces albuminuria in rats without affecting blood pressure [1].
Derenofylline 动物研究
Animal study
Derenofylline (0.3-10 mg/kg, orally administered) mitigates adenosine-induced bradycardia in rats [1].Derenofylline (10 mg/kg/d, oral administration, 12 weeks) diminishes myocardial fibrosis in 5/6 nephrectomy rats without altering blood pressure [1].Derenofylline (0.1-5 mg/kg, intravenous injection) does not induce major hemodynamic effects (heart rate and blood pressure) [1].
搜索
